Fulcrum Therapeutics, Inc.
FULC
$3.74
$0.030.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 705.00K | 14.08M | 15.42M | 14.30M | 555.00K |
| Gross Profit | -705.00K | -14.08M | -15.42M | -14.30M | -555.00K |
| SG&A Expenses | 7.46M | 8.10M | 7.28M | 7.56M | 6.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.91M | 22.19M | 22.69M | 21.86M | 19.82M |
| Operating Income | -19.91M | -22.19M | -22.69M | -21.86M | -19.82M |
| Income Before Tax | -26.18M | -18.89M | -20.33M | -19.60M | -17.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.18M | -18.89M | -20.33M | -19.60M | -17.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.18M | -18.89M | -20.33M | -19.60M | -17.30M |
| EBIT | -19.91M | -22.19M | -22.69M | -21.86M | -19.82M |
| EBITDA | -19.69M | -21.85M | -22.35M | -21.51M | -19.47M |
| EPS Basic | -0.34 | -0.25 | -0.31 | -0.31 | -0.28 |
| Normalized Basic EPS | -0.14 | -0.15 | -0.19 | -0.20 | -0.17 |
| EPS Diluted | -0.34 | -0.25 | -0.31 | -0.31 | -0.28 |
| Normalized Diluted EPS | -0.14 | -0.15 | -0.19 | -0.20 | -0.17 |
| Average Basic Shares Outstanding | 76.26M | 76.22M | 65.78M | 62.60M | 62.54M |
| Average Diluted Shares Outstanding | 76.26M | 76.22M | 65.78M | 62.60M | 62.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |